Hepatic Adenomas in Men: Diagnostic Considerations and Management in the Modern Era
Journal of Surgical Oncology · 18.10.2026
DOI: 10.1002/jso.70415 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Journal of Surgical Oncology, online erschienen am 18.10.2026. Verfasst von Teresa Belledent und 9 weiteren Autor:innen. Beteiligte Einrichtung: Meharry Medical College, Nashville, Tennessee, USA. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 49 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Hepatic adenomas (HAs) are rare benign liver tumors traditionally associated with young women, yet contemporary epidemiologic trends reveal increasing recognition among men. Historically, universal resection in males has been recommended because of a nearly tenfold increased risk of malignant transformation as reported by Farges et al. in a single‐institution surgical series ; however, advances in molecular profiling and imaging have challenged this paradigm. β‐catenin–activated and inflammatory subtypes account for most cases in men, often associated with anabolic steroid exposure, obesity, or metabolic syndrome. β‐catenin‐activated adenomas—particularly those harboring CTNNB1 exon 3 mutations—demonstrate the strongest correlation with malignant potential. Magnetic resonance imaging with hepatobiliary contrast agents can suggest subtype but lacks perfect accuracy; biopsy offers improved diagnostic precision and enables molecular confirmation. Current ACG and EASL guidelines still endorse routine resection for all hepatic adenomas in males; however, available retrospective data suggest that malignant transformation appears to be uncommon in small (5 cm) lesions lacking exon 3 CTNNB1 mutations; however, this observation is derived from limited, predominantly retrospective data and does not exclude the possibility of malignant transformation in this subgroup. These data support selective, biopsy‐guided surveillance for small, indeterminate tumors within experienced multidisciplinary centers where longitudinal follow‐up is reliable. Resection remains the standard recommendation for large or β‐catenin–mutated adenomas, with minimally invasive surgery demonstrating excellent outcomes. Modern management of hepatic adenomas in men should be individualized, integrating molecular subtype, size, risk factors, and patient context. A multidisciplinary and molecularly informed strategy is essential to optimize outcomes while avoiding unnecessary intervention.
Autor:innen und Institutionen
- Meharry Medical College, Nashville, Tennessee, USA.
- University of Louisville School of Medicine, Louisville, Kentucky, USA.
- Department of Biology, University of Iowa, Iowa City, Iowa, USA.
- Carver College of Medicine, University of Iowa, Iowa City, Iowa, USA.
- Department of Surgery, The Ohio State University Wexner Medical Center, Columbus, Ohio, USA.
- Department of Surgery, University of Iowa Hospitals and Clinics, Iowa City, Iowa, USA.
ORCID-Profile: Teresa Belledent, Timothy Pawlik, Terry L Hayes, Mohammed O Suraju, Hassan Aziz
Zitieren
APA
Belledent, T., Nwosu, J., Brevik, K., Abbey, R. M., Pawlik, T., Hwang, D. S., Hayes, T. L., Nwosu, I., Suraju, M. O., & Aziz, H. (2026). Hepatic Adenomas in Men: Diagnostic Considerations and Management in the Modern Era. Journal of Surgical Oncology. https://doi.org/10.1002/jso.70415
Vancouver
Belledent T, Nwosu J, Brevik K, Abbey RM, Pawlik T, Hwang DS, et al. Hepatic Adenomas in Men: Diagnostic Considerations and Management in the Modern Era. Journal of Surgical Oncology. 2026. doi:10.1002/jso.70415
BibTeX
@article{Belledent2026,
author = {Belledent, Teresa and Nwosu, Julie and Brevik, Kiers and Abbey, Raegen M and Pawlik, Timothy and Hwang, Dae Sun and Hayes, Terry L and Nwosu, Ikenna and Suraju, Mohammed O and Aziz, Hassan},
title = {Hepatic Adenomas in Men: Diagnostic Considerations and Management in the Modern Era},
journal = {Journal of Surgical Oncology},
year = {2026},
doi = {10.1002/jso.70415}
}
EUVIMED